Capecitabine as third line therapy in patients with advanced colorectal cancer

By Gubanski Michael   Naucler Gisela   Almerud Agneta   Lideståhl Anders   Lind Pehr A R M  

Acta Oncologica, Vol. 44, Iss. 3, 2005-05 ,pp. : 236-239

Informa Healthcare

Access to resources Recommend Favorite

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

By Rosati Gerardo   Avallone Antonio   Aprile Giuseppe   Butera Alfredo   Reggiardo Giorgio   Bilancia Domenico  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 257-264

Springer Publishing Company

Access to resources Recommend Favorite

Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 9, 2013-11 ,pp. : 1344-1353

Bentham Science Publishers

Access to resources Recommend Favorite

Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer

By Larsen Finn Ole   Boisen Mogens Karsbøl   Fromm Annelene L.   Jensen Benny Vittrup  

Acta Oncologica, Vol. 51, Iss. 2, 2012-02 ,pp. : 231-233

Informa Healthcare

Access to resources Recommend Favorite

Palliative care programs for patients with breast cancer: the benefits of home-based care

By Seow Hsien   Bainbridge Daryl   Bryant Deanna  

Breast Cancer Management, Vol. 2, Iss. 5, 2013-09 ,pp. : 407-416

Future Medicine

Access to resources Recommend Favorite